Overview

LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: - Induction ends on day 19 - Consolidation ends on day 38 or 42 - Maintenance may include up to 6 cycles
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Asparaginase
Cyclophosphamide
Daunorubicin
Methotrexate